Program Committee
-
Daisaku Sato, PHD, MPHARM, RPH Councilor for Pharmaceutical Affairs
Ministry of Health, Labour and Welfare, Japan -
Yasuko Terao, PHD Head, External Scientific Engagement, R&D Japan Region,
Takeda Pharmaceutical Co., Ltd., Japan -
Teruyo Arato, PHD Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan -
Masaki Kasai, PHD Review Director, Office of Pharmacovigilance II
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yoshie Tsurumaki
HEALIOS K.K., Japan -
Kazunobu Oyama, PHD CMC Regulatory Affairs, Director
Daiichi Sankyo Company, Limited, Japan -
Hiromi Okabe, PHD Oncology & Rare Disease, Regulatory Strategy, Regulatory Affairs
Amgen K.K., Japan -
Masafumi Onodera, MD, PHD Director, Center of Gene Cell Therapy Promotion,
National Center for Child Health and Development, Japan -
Satoru Hayata, MS
Sobi Japan, Japan -
Hiroyuki Suda, MSC VP, Clinical Development Strategy
KORTUC Inc., Japan -
Sumimasa Nagai, MD, PHD Institute for Advancement of Clinical and Translational Science(iACT)
Kyoto University Hospital, Japan -
Yoji Sato, PHD Deputy Director General
National Institute of Health Sciences, Japan -
Akiko Ikeda, RPH PRIMO, External Researcher/Consultant
National Cancer Center, Japan
Have an account?